NEGATIVE REGULATION OF AUTOREACTIVE T-CELLS

自身反应性 T 细胞的负调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): This is a proposal to explore the mechanisms of long-term tolerance of autoreactive CD4 T-cells induced by soluble MHC II/Fc/peptide chimeras. Our preliminary results indicated that short therapy with MHC II/Fc/peptide chimeras of prediabetic mice induced regulatory mechanisms responsible for tolerance to a self autoantigen, and offered protection against the disease onset for as long as 8 months. Using a double transgenic mouse model for insulin-dependent diabetes mellitus (IDDM) in which the autoreactive T-cells specific for a defined self epitope were not deleted by thymic selection, and they were not tolerized in periphery, we propose to explore the cellular, and molecular mechanisms induced by MHC II/Fc/peptide chimera leading to antigen-specific long-term tolerance. Manipulation of the antigen-specific tolerance to immunodominant autoreactive epitopes in the neonatal life, may soon lead to novel strategies aimed at arresting the epitope spreading in autoimmune diseases. Deciphering the cellular and molecular basis of these mechanisms may also offer a better understanding of why antigen-specific long-term tolerance can be easily induced in the neonatal life, but not in the adult life. In the first part of this application we will (1) investigate the ability of MHC II/Fc/peptide chimera to induce protective Th2 memory responses and regulatory/suppressor cells during particular age-windows, (2) characterize immunophenotypically and functionally the fate of these cells in adulthood, and (3) define their protective capacity against autoimmune diabetes in the IDDM double transgenic mouse model. In the second part, we will (1) explore the biochemical nature of several transductional and transcriptional events that can be differentially induced by MHC II/Fc/peptide chimera in early life, and that may affect the fate of Th2 and regulatory/suppressor cells in adulthood, and (2) investigate the biochemical nature of tolerogenic signals induced by regulatory/suppressor cells in the autoreactive T-cells in the target organ. Satisfactory results of this study will expand our area of investigations on the human MHC II/Fc/peptide-like reagents carrying immunodominant autoreactive epitopes relevant for human autoimmune diseases. The antigen-specific tolerogenicity of these reagents will be evaluated in in vitro systems, and in double transgenic mice deficient for the murine MHC class II, and expressing human HLA-DR* alleles.
描述(由申请人提供):这是一份探索

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TEODOR-DORU BRUMEANU BRUMEANU其他文献

TEODOR-DORU BRUMEANU BRUMEANU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TEODOR-DORU BRUMEANU BRUMEANU', 18)}}的其他基金

Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
  • 批准号:
    6524692
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
NEGATIVE REGULATION OF AUTOREACTIVE T-CELLS
自身反应性 T 细胞的负调节
  • 批准号:
    6353266
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
  • 批准号:
    6931625
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
  • 批准号:
    6892222
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
  • 批准号:
    6789342
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
NEGATIVE REGULATION OF AUTOREACTIVE T-CELLS
自身反应性 T 细胞的负调控
  • 批准号:
    6892223
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
NEGATIVE REGULATION OF AUTOREACTIVE T-CELLS
自身反应性 T 细胞的负调控
  • 批准号:
    6603103
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
  • 批准号:
    6500182
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
  • 批准号:
    6647111
  • 财政年份:
    2001
  • 资助金额:
    $ 21.19万
  • 项目类别:
DOWN-REGULATION OF DIABETOGENIC T-CELLS
下调糖尿病 T 细胞
  • 批准号:
    6055867
  • 财政年份:
    2000
  • 资助金额:
    $ 21.19万
  • 项目类别:

相似海外基金

The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
  • 批准号:
    DP240102905
  • 财政年份:
    2024
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23K28188
  • 财政年份:
    2024
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
  • 批准号:
    2339172
  • 财政年份:
    2024
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
  • 批准号:
    10577518
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23H03498
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
  • 批准号:
    10676407
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
  • 批准号:
    22KK0277
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
  • 批准号:
    10599584
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
  • 批准号:
    10530023
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
  • 批准号:
    10684172
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了